GeneticsbioRxivPreprint
Ultra-deep sequencing reveals no evidence of oncogenic mutations or enrichment by ex vivo CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells
M. Kyle Cromer, Valentin V. Barsan, Erich B. Jaeger…·Matthew Hebden Porteus
The paper uses ultra-deep sequencing to assess oncogenic mutations in human hematopoietic stem and progenitor cells after CRISPR/Cas9 editing, finding no evidence of tumorigenic variants.
DOI 10.1101/2021.10.27.466166